Alle Studien
RekrutierungPHASE2INTERVENTIONELL

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

This study is investigating a new medication, sotatercept, for children and teenagers aged 1 to 17 who have a specific type of pulmonary arterial hypertension (PAH). PAH is a serious condition where blood vessels in the lungs become narrow, making it hard for the heart to pump blood. The main goals are to check if sotatercept is safe for young people and how well their bodies handle the medicine over 24 weeks. Participants will continue to receive their standard PAH treatments while taking part. This is an early-stage study, meaning we are still learning about this medicine, and it's not designed to prove if the medicine works better than current treatments, but rather to understand its safety and how it behaves in children.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE2
Sponsor
Merck Sharp & Dohme LLC
Einschreibeziel
42
Starten
19. Jan 2023
Geschätzte Fertigstellung
21 Sep 2028

Worum geht es in dieser Studie?

This study is looking into a new medicine called sotatercept for children and teenagers between 1 and 17 years old who have a serious lung condition called pulmonary arterial hypertension. PAH happens when the blood vessels in the lungs become narrow and stiff, making it difficult for the heart to pump blood through them. This can cause the heart to work too hard.

The main reasons for this study are to see if sotatercept is safe for young people and to understand how their bodies process the medicine over 24 weeks. Participants will continue taking their usual PAH medicines during the study. This is an important step in developing new treatments for PAH in children. By understanding how sotatercept behaves in younger patients, doctors can learn more about its potential use.

It's important to know that this is a 'Phase 2' study. This means it's an early step in testing a new medicine. We're not yet trying to prove if the medicine works better than existing treatments, but rather focusing on its safety and gathering initial information on how it works in the body. This kind of research is vital for bringing new and potentially helpful medicines to those who need them.

Wichtige Erkenntnisse

  • This study is for children aged 1-17 with a specific type of PAH.
  • It's testing a new medicine called sotatercept for safety and how the body handles it.
  • Participants will continue their usual PAH treatments.
  • This is an early-stage study (Phase 2) to gather important information.
  • Participation involves regular clinic visits for monitoring.
  • You can withdraw from the study at any time without affecting your child's care.

Wer könnte berechtigt sein?

To join this study, a child must have a confirmed diagnosis of a specific type of pulmonary arterial hypertension (PAH), which would have been diagnosed through a special heart test called a right heart catheterisation. This diagnosis must have happened before screening for the study. The types of PAH covered include those that run in families, those caused by certain drugs, or PAH linked to other conditions like connective tissue disease.

Children need to be between 1 and 17 years old. They must also already be on a steady dose of their usual PAH medicines, such as those that relax blood vessels or help open them up. These medicines must have been taken consistently without changes for a while before the study starts.

There are also important rules about avoiding pregnancy during the study and for some time after the last dose of the study medicine, for both male and female participants. This is because we don't know the effects of the study medicine on an unborn baby. For example, specific contraception methods or agreement to not have PIV during this period would be necessary. Also, participants cannot donate blood or sperm during the study.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Is your child aged between 1 and 17 years old?
  2. Does your child have a confirmed diagnosis of a specific type of PAH?
  3. Is your child currently taking a steady dose of their usual PAH medicines?
  4. Are you able to follow specific rules about avoiding pregnancy during and after the study for your child?
  5. Has your child had their PAH diagnosis confirmed by a special heart test called a right heart catheterization?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you or your child decides to take part, they will receive the study medicine, sotatercept, for 24 weeks, while continuing all their usual PAH treatments. During this time, there will be regular visits to the clinic so the study team can monitor their health, perform necessary tests, and make sure the medicine is being taken safely. These tests might include blood samples, physical examinations, and other checks related to their heart and lungs. After the 24 weeks of treatment, there will be some follow-up visits to ensure your child is doing well and to collect final information. The exact number of visits and tests will be explained in detail by the study doctor, and the total duration of your child's involvement would be beyond the 24 weeks of treatment, including follow-up time.

Potenzielle Risiken und Vorteile

Taking part in any study has potential benefits and risks. Your child might not directly benefit from taking sotatercept, as this is an early-stage study focused on safety. However, they would be helping doctors learn more about PAH and potentially contribute to new treatments for others in the future. Potential risks might include side effects from the study medicine, which would be carefully monitored by the study team. They will explain all known side effects. You are free to withdraw your child from the study at any time, for any reason, and this will not affect their regular medical care.

Locations (35)

  • The Regents of the University of California - Los Angeles (UCLA Pediatrics) ( Site 1606)
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Rekrutierung
  • Stanford University School of Medicine ( Site 1603)
    Verifizierte Postleitzahl
    Palo Alto, Vereinigte Staaten· Rekrutierung
  • UCSF Benioff Children's Hospital San Francisco ( Site 1611)
    Verifizierte Postleitzahl
    San Francisco, Vereinigte Staaten· Rekrutierung
  • Children's Hospital Colorado ( Site 1609)
    Verifizierte Postleitzahl
    Aurora, Vereinigte Staaten· Rekrutierung
  • Children's National Medical Center ( Site 1600)
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten· Rekrutierung
  • Cincinnati Children's Hospital Medical Center ( Site 1602)
    Verifizierte Postleitzahl
    Cincinnati, Vereinigte Staaten· Rekrutierung
  • Children's Hospital of Philadelphia (CHOP) ( Site 1608)
    Verifizierte Postleitzahl
    Philadelphia, Vereinigte Staaten· Rekrutierung
  • Monroe Carell Jr. Children's Hospital ( Site 1601)
    Verifizierte Postleitzahl
    Nashville, Vereinigte Staaten· Abgeschlossen
  • Seattle Children's Hospital ( Site 1605)
    Verifizierte Postleitzahl
    Seattle, Vereinigte Staaten· Rekrutierung
  • Children's Wisconsin ( Site 1610)
    Verifizierte Postleitzahl
    Milwaukee, Vereinigte Staaten· Rekrutierung
  • The Children's Hospital at Westmead ( Site 0001)
    Verifizierte Postleitzahl
    Westmead, Australia· Rekrutierung
  • Clinica Somer-Unidad de Investigacion y Docencia ( Site 0205)
    Verifizierte Postleitzahl
    Rionegro, Colombia· Rekrutierung

Häufige Fragen

What is Pulmonary Arterial Hypertension (PAH)?

PAH is a serious lung condition where the blood vessels in the lungs become narrow, making it hard for the heart to pump blood through them.

Was ist der Zweck dieser Studie?

This study aims to find out if the new medicine, sotatercept, is safe for children with PAH and how their bodies handle it over 24 weeks, alongside their usual treatments.

Will my child stop their current PAH medicines if they join?

No, your child will continue to take their usual PAH medicines during the study. Sotatercept would be an additional treatment.

What does 'Phase 2' study mean?

Phase 2 means it's an early stage of testing a new medicine. We're focusing on safety and initial understanding, not yet proving it works better than other treatments.

Can we stop participating at any time?

Yes, you can choose to withdraw your child from the study at any point, and it will not affect their medical care.

Wie Sie mehr erfahren können

Gebührenfreie Nummer

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Study to Evaluate Sotatercept (MK-7962) in Children With Pul… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.